nature.com
GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity
This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings that could affect decisions about metabolic therapy in people with IBD but which are not definitive.
Adults with Crohn’s disease and obesity, clinicians managing IBD and metabolic comorbidities, and researchers studying GLP-1RAs or IBD outcomes.
What To Know
What to know This observational, propensity score–matched cohort study used the TriNetX electronic health record network to compare adults with Crohn’s disease and obesity who started GLP-1 receptor agonists (GLP-1RAs) versus matched nonusers.
Over 1- and 5-year fixed horizons the authors report lower mortality, fewer hospitalizations and ED visits, and lower subsequent TNF inhibitor use among GLP-1RA initiators; corticosteroid use was similar at 1 year and modestly lower at 5 years.
The study is retrospective and relies on EHR data with limited information about individual drug exposure (adherence, discontinuation, or switching). The authors note possible healthy-user bias and caution that the mortality difference should be considered hypothesis-generating rather than proof of a causal benefit.
The lower TNF inhibitor rate should not be interpreted as definitive evidence of less treatment escalation because initiation versus continuation could not be distinguished.
If you or your clinician are considering a GLP-1RA for weight or metabolic reasons, this study provides reassuring real-world safety signals in people with Crohn’s disease and obesity and suggests possible associations with lower healthcare use that deserve prospective study. It does not replace clinical judgment or randomized trial evidence.
Study details such as which specific GLP-1 agents were used, duration and adherence, and reasons for TNF inhibitor prescriptions are not fully captured in the database; prospective studies are needed to confirm these associations.
Retrospective EHR analyses can show associations but cannot prove cause-and-effect. Important exposure details (adherence, switching) were unavailable and healthy-user bias may influence results; the authors recommend prospective evaluation.
